GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inoviq Ltd (ASX:IIQ) » Definitions » Total Liabilities

Inoviq (ASX:IIQ) Total Liabilities : A$1.66 Mil (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Inoviq Total Liabilities?

Inoviq's Total Liabilities for the quarter that ended in Dec. 2023 was A$1.66 Mil.

Inoviq's quarterly Total Liabilities declined from Dec. 2022 (A$3.09 Mil) to Jun. 2023 (A$1.89 Mil) and declined from Jun. 2023 (A$1.89 Mil) to Dec. 2023 (A$1.66 Mil).

Inoviq's annual Total Liabilities declined from Jun. 2021 (A$4.47 Mil) to Jun. 2022 (A$2.49 Mil) and declined from Jun. 2022 (A$2.49 Mil) to Jun. 2023 (A$1.89 Mil).


Inoviq Total Liabilities Historical Data

The historical data trend for Inoviq's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inoviq Total Liabilities Chart

Inoviq Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.49 0.90 4.47 2.49 1.89

Inoviq Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.51 2.49 3.09 1.89 1.66

Inoviq Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Inoviq's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.518+(0.368+6.0715321659188E-18
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.007)
=1.89

Total Liabilities=Total Assets (A: Jun. 2023 )-Total Equity (A: Jun. 2023 )
=21.509-19.615
=1.89

Inoviq's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.403+(0.244+0.014
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1.66

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=18.406-16.744
=1.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inoviq Total Liabilities Related Terms

Thank you for viewing the detailed overview of Inoviq's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Inoviq (ASX:IIQ) Business Description

Traded in Other Exchanges
N/A
Address
23 Normanby Road, Notting Hill, Melbourne, VIC, AUS, 3168
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.

Inoviq (ASX:IIQ) Headlines

No Headlines